178 related articles for article (PubMed ID: 20020310)
1. Structure-based and shape-complemented pharmacophore modeling for the discovery of novel checkpoint kinase 1 inhibitors.
Chen XM; Lu T; Lu S; Li HF; Yuan HL; Ran T; Liu HC; Chen YD
J Mol Model; 2010 Jul; 16(7):1195-204. PubMed ID: 20020310
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Pharmacophore Modeling from Multicomplex: a Comprehensive Pharmacophore Generation of Protein Kinase CK2 and Virtual Screening Based on it for Novel Inhibitors.
Sun HP; Zhu J; Chen FH; You QD
Mol Inform; 2011 Jun; 30(6-7):579-92. PubMed ID: 27467158
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore modeling and virtual screening studies of checkpoint kinase 1 inhibitors.
Chen JJ; Liu TL; Yang LJ; Li LL; Wei YQ; Yang SY
Chem Pharm Bull (Tokyo); 2009 Jul; 57(7):704-9. PubMed ID: 19571415
[TBL] [Abstract][Full Text] [Related]
4. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
Oza V; Ashwell S; Almeida L; Brassil P; Breed J; Deng C; Gero T; Grondine M; Horn C; Ioannidis S; Liu D; Lyne P; Newcombe N; Pass M; Read J; Ready S; Rowsell S; Su M; Toader D; Vasbinder M; Yu D; Yu Y; Xue Y; Zabludoff S; Janetka J
J Med Chem; 2012 Jun; 55(11):5130-42. PubMed ID: 22551018
[TBL] [Abstract][Full Text] [Related]
5. Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening.
Foloppe N; Fisher LM; Howes R; Potter A; Robertson AG; Surgenor AE
Bioorg Med Chem; 2006 Jul; 14(14):4792-802. PubMed ID: 16574416
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.
Zhao L; Zhang Y; Dai C; Guzi T; Wiswell D; Seghezzi W; Parry D; Fischmann T; Siddiqui MA
Bioorg Med Chem Lett; 2010 Dec; 20(24):7216-21. PubMed ID: 21074424
[TBL] [Abstract][Full Text] [Related]
7. Ligand-based and structure-based approaches in identifying ideal pharmacophore against c-Jun N-terminal kinase-3.
Kumar BV; Kotla R; Buddiga R; Roy J; Singh SS; Gundla R; Ravikumar M; Sarma JA
J Mol Model; 2011 Jan; 17(1):151-63. PubMed ID: 20393763
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel checkpoint kinase 1 inhibitors by virtual screening based on multiple crystal structures.
Li Y; Kim DJ; Ma W; Lubet RA; Bode AM; Dong Z
J Chem Inf Model; 2011 Nov; 51(11):2904-14. PubMed ID: 21955044
[TBL] [Abstract][Full Text] [Related]
9. Computational studies on the binding mechanism between triazolone inhibitors and Chk1 by molecular docking and molecular dynamics.
Lv M; Ma S; Tian Y; Zhang X; Lv W; Zhai H
Mol Biosyst; 2015 Jan; 11(1):275-86. PubMed ID: 25372494
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling, molecular docking and molecular dynamics simulations toward identifying lead compounds for Chk1.
Li Y; Peng J; Zhou Y; Li P; Li Y; Liu X; Siddique AN; Zhang L; Zuo Z
Comput Biol Chem; 2018 Oct; 76():53-60. PubMed ID: 29940486
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH
J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464
[TBL] [Abstract][Full Text] [Related]
12. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity.
Foloppe N; Fisher LM; Howes R; Kierstan P; Potter A; Robertson AG; Surgenor AE
J Med Chem; 2005 Jun; 48(13):4332-45. PubMed ID: 15974586
[TBL] [Abstract][Full Text] [Related]
14. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 1.
Dwyer MP; Paruch K; Labroli M; Alvarez C; Keertikar KM; Poker C; Rossman R; Fischmann TO; Duca JS; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):467-70. PubMed ID: 21094608
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
16. Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis.
Pathak D; Chadha N; Silakari O
J Mol Graph Model; 2016 Nov; 70():85-93. PubMed ID: 27693947
[TBL] [Abstract][Full Text] [Related]
17. Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: a template-based approach--part 2.
Labroli M; Paruch K; Dwyer MP; Alvarez C; Keertikar K; Poker C; Rossman R; Duca JS; Fischmann TO; Madison V; Parry D; Davis N; Seghezzi W; Wiswell D; Guzi TJ
Bioorg Med Chem Lett; 2011 Jan; 21(1):471-4. PubMed ID: 21094607
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel inhibitors of human Chk1 using pharmacophore-based virtual screening and their evaluation as potential anti-cancer agents.
Kumar V; Khan S; Gupta P; Rastogi N; Mishra DP; Ahmed S; Siddiqi MI
J Comput Aided Mol Des; 2014 Dec; 28(12):1247-56. PubMed ID: 25312395
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
Vyas VK; Ghate M; Goel A
J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors.
Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK
Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
